| 1741 |
LUCILENA |
LENALIDOMIDE 25 MG |
CAPSULE |
BOTTLE |
FOR THE TREATMENT OF ADULT PATIENTS WITH MULTIPLE MYELOMA IN COMBINATION WITH DEXAMETHASONE, MULTIPLE MYELOM, AS MAINTENANCE FOLLOWING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION |
NULL |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LAOS |
CERTIFICATE RELEASED |
12 L 1282/24 |
23-JAN-2025 |
22-JAN-2030 |
View |
| 1742 |
LUCILENACAP |
LENACAPAVIR 300 MG |
TABLET |
BOTTLE |
FOR THE TREATMENT OF HIV-1 INFECTION IN HEAVILY TREATMENT -EXPERIENCED ADULTS WITH MULTIDRUG RESISTANT HIV-1 INFECTION FAILING THEIR CURRENT ANTIRETROVIRAL REGIMEN DUE TORESISTANCE, INTOLERANCE, OR SAFETY CONSIDERATION |
NULL |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LAOS |
CERTIFICATE RELEASED |
03 L 1316/25 |
07-APR-2025 |
06-APR-2030 |
View |
| 1743 |
LUCILENVA 10 MG |
LENVATINIB 10 MG |
CAPSULE |
BOTTLE |
FOR THE TREATMENT OF PATIENTS WITH LOCALLY RECURRENT OR METASTATIC, PROGRESSIVE, RADIOACTIVE IODINE REFRACTORY DIFFERENTIATED THYROID CANCER |
NULL |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LAOS |
CERTIFICATE RELEASED |
03 L 1080/24 |
26-Mar-2024 |
25-Mar-2027 |
View |
| 1744 |
LUCILENVA 4 MG |
LENVATINIB 4 MG |
CAPSULE |
BOTTLE |
FOR THE TREATMENT OF PATIENTS WITH LOCALLY RECURRENT OR METASTATIC, PROGRESSIVE, RADIOACTIVE IODINE REFRACTORY DIFFERENTIATED THYROID CANCER |
NULL |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LAOS |
CERTIFICATE RELEASED |
03 L 1079/24 |
26-Mar-2024 |
25-Mar-2027 |
View |
| 1745 |
LUCILETER |
LETERMOVIR 240 MG |
TABLET |
BOTTLE |
FOR PROPHYLAXIS OF CYTOMEGALOVIRUS INFECTION AND DISESEASE IN ADULT AND PAEDIATRIC PATIENTS 6 MONTHS OF GAE AND OLDER AND WEIGHING AT LEAST 6 KG WHO ARE CMV-SEROPOSITIVE RECIEPIENTS OF AN ALLOGENEIC HEMATOPOITIC STEM CELL TRANSPLANT, PROPHYLAXIS OF CMV DISEASE IN ADULT AND PAEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER AND WEIGHNING AT LEAST 40 KG WHO ARE KIDNEY TRANSPLANT RECEIPIENTS AT HIGH RISK (DONOR CMV SEROPOSITIVE/RECIPEINT CMV SERONEGATIVE) |
NULL |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LAOS |
CERTIFICATE RELEASED |
04 L 1340/25 |
2025-04-21 |
2030-04-20 |
View |
| 1746 |
LUCILORLA |
LORLATINIB 100 MG |
TABLET |
BOTTLE |
TREATMENT OF METASTATIC NON SMALL CELL LUNG CANCER |
NULL |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LAOS |
CERTIFICATE RELEASED |
07 L 0987/23 |
21-Jul-2023 |
20-Jul-2026 |
View |
| 1747 |
LUCILORLA |
LORLATINIB 25 MG |
TABLET |
BOTTLE |
TREATMENT OF METASTATIC NON SMALL CELL LUNG CANCER |
NULL |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LAOS |
CERTIFICATE RELEASED |
07 L 0989/23 |
21-Jul-2023 |
20-Jul-2026 |
View |
| 1748 |
LUCILUSU 3 MG |
LUSUTROMBOPAG 3 MG |
TABLET |
BLISTERPACK |
TREATMENT OF THROMBOCYTOPENIA IN ADULT PATIENTS WITH CHRONIC LIVER DISEASE WHO ARESCHEDULED TO UNDERGO PROCEDURE |
NULL |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LAOS |
CERTIFICATE RELEASED |
11 L 1250/24 |
03-DEC-2024 |
02-DEC-2029 |
View |
| 1749 |
LUCIMACI |
MACITENTAN 10 MG |
TABLET |
BOTTLE |
FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION TO REDUCE THE RISKS OF DISEASE PROGRESSION AND HOSPITALIZATION FOR PULMONARY ARTERIAL HYPERTENSION |
NULL |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LAOS |
CERTIFICATE RELEASED |
03 L 1320/25 |
07-APR-2025 |
06-APR-2030 |
View |
| 1750 |
LUCIMAVA |
MAVACAMTEN 2.5 MG |
CAPSULE |
BOTTLE |
FOR THE TREATMENT OF ADULTS WITH SYMPTOMATIC NEW YORK HEART ASSOCIATION CLASS II-III OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY TO IMPROVE FUNCTIONAL CAPACITY AND SYMPTOMS |
NULL |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LAOS |
CERTIFICATE RELEASED |
09 L 1198/24 |
24-SEP-2024 |
23-SEP-2029 |
View |
